

Clinical trials need to better protect participants and research integrity as data accumulate

June 12 2012

An Essay by Susan Ellenberg from the University of Pennsylvania describes alternative approaches to the evaluation of clinical trials, with the objectives both of preventing undue risks to participants and protecting the integrity of data.

Writing in this week's <u>PLoS Medicine</u>, the author outlines the importance of methods for ensuring independence of those involved in analysis of interim data, and for ensuring that early stopping guidelines are clearly laid out before a trial starts.

However, the author emphasises that issues around liability for individuals who provide these functions are currently unclear, and concludes: "DMCs [data monitoring committees] have become expected components of many <u>clinical trials</u>, and provide an important oversight function".

More information: Ellenberg SS (2012) Protecting Clinical Trial Participants and Protecting Data Integrity: Are We Meeting the Challenges? PLoS Med 9(6): e1001234. doi:10.1371/journal.pmed.1001234

Provided by Public Library of Science



Citation: Clinical trials need to better protect participants and research integrity as data accumulate (2012, June 12) retrieved 4 May 2024 from https://medicalxpress.com/news/2012-06-clinical-trials-accumulate.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.